149 related articles for article (PubMed ID: 18595128)
1. Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.
Pearlman BL
World J Gastroenterol; 2008 Jun; 14(23):3621-7. PubMed ID: 18595128
[TBL] [Abstract][Full Text] [Related]
2. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.
Farnik H; Lange CM; Sarrazin C; Kronenberger B; Zeuzem S; Herrmann E
Clin Gastroenterol Hepatol; 2010 Oct; 8(10):884-90. PubMed ID: 20601130
[TBL] [Abstract][Full Text] [Related]
4. [Retreatment options for patients with chronic hepatitis C].
Hrstić I; Ostojić R; Vucelić B
Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
[TBL] [Abstract][Full Text] [Related]
5. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
6. [24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia].
Moon SS; Kang HG; Seo JA; Jung EU; Lee SH; Park SJ; Lee YJ; Seol SY
Korean J Gastroenterol; 2010 Jul; 56(1):33-8. PubMed ID: 20664316
[TBL] [Abstract][Full Text] [Related]
7. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
[TBL] [Abstract][Full Text] [Related]
9. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.
Sood A; Midha V; Goyal O
Ann Hepatol; 2014; 13(5):503-9. PubMed ID: 25152982
[TBL] [Abstract][Full Text] [Related]
11. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
[TBL] [Abstract][Full Text] [Related]
12. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
13. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Berg T; von Wagner M; Nasser S; Sarrazin C; Heintges T; Gerlach T; Buggisch P; Goeser T; Rasenack J; Pape GR; Schmidt WE; Kallinowski B; Klinker H; Spengler U; Martus P; Alshuth U; Zeuzem S
Gastroenterology; 2006 Apr; 130(4):1086-97. PubMed ID: 16618403
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
15. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Núñez M; Mariño A; Miralles C; Berdún MA; Sola J; Hernandez-Burruezo JJ; Galindo MJ; Barreiro P; Martin-Carbonero L; Soriano V
J Acquir Immune Defic Syndr; 2007 Aug; 45(4):439-44. PubMed ID: 17468669
[TBL] [Abstract][Full Text] [Related]
16. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Hadziyannis SJ; Sette H; Morgan TR; Balan V; Diago M; Marcellin P; Ramadori G; Bodenheimer H; Bernstein D; Rizzetto M; Zeuzem S; Pockros PJ; Lin A; Ackrill AM;
Ann Intern Med; 2004 Mar; 140(5):346-55. PubMed ID: 14996676
[TBL] [Abstract][Full Text] [Related]
18. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
Chevaliez S; Hézode C; Soulier A; Costes B; Bouvier-Alias M; Rouanet S; Foucher J; Bronowicki JP; Tran A; Rosa I; Mathurin P; Alric L; Leroy V; Couzigou P; Mallat A; Charaf-Eddine M; Babany G; Pawlotsky JM
Gastroenterology; 2011 Jul; 141(1):119-27. PubMed ID: 21439960
[TBL] [Abstract][Full Text] [Related]
19. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
Di Martino V; Richou C; Cervoni JP; Sanchez-Tapias JM; Jensen DM; Mangia A; Buti M; Sheppard F; Ferenci P; Thévenot T
Hepatology; 2011 Sep; 54(3):789-800. PubMed ID: 21674553
[TBL] [Abstract][Full Text] [Related]
20. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?
Marcellin P; Heathcote EJ; Craxì A
J Hepatol; 2007 Oct; 47(4):580-7. PubMed ID: 17692991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
